骨髄異形成症候群（MDS）治療薬の世界市場（～2026年）

• 英文タイトル：Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY03884 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は骨髄異形成症候群（MDS）治療薬のグローバル市場について調査・分析したレポートです。種類別（アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他）市場規模、用途別（入院患者、外来患者）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別骨髄異形成症候群（MDS）治療薬の競争状況、市場シェア ・世界の骨髄異形成症候群（MDS）治療薬市場：種類別市場規模 2015年-2020年（アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他） ・世界の骨髄異形成症候群（MDS）治療薬市場：種類別市場規模予測 2021年-2026年（アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他） ・世界の骨髄異形成症候群（MDS）治療薬市場：用途別市場規模 2015年-2020年（入院患者、外来患者） ・世界の骨髄異形成症候群（MDS）治療薬市場：用途別市場規模予測 2021年-2026年（入院患者、外来患者） ・北米の骨髄異形成症候群（MDS）治療薬市場分析：米国、カナダ ・ヨーロッパの骨髄異形成症候群（MDS）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの骨髄異形成症候群（MDS）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の骨髄異形成症候群（MDS）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの骨髄異形成症候群（MDS）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Novartis AG、Celgene Corporation、Otsuka Pharmaceutical Co., Ltd.、Sandoz Inc.、Dr Reddys Laboratories Limited、Pharmascience Inc.、Accord Healthcare Ltd、Mylan N.V. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Myelodysplastic Syndrome (MDS) Therapeutics Market
The global Myelodysplastic Syndrome (MDS) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Myelodysplastic Syndrome (MDS) Therapeutics Scope and Market Size
Myelodysplastic Syndrome (MDS) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myelodysplastic Syndrome (MDS) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd.
Sandoz Inc.
Dr Reddys Laboratories Limited
Pharmascience Inc.
Accord Healthcare Ltd
Mylan N.V.

Market segment by Type, the product can be split into
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Others
Market segment by Application, split into
In-Patient
Out-Patient

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Myelodysplastic Syndrome (MDS) Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Azacitidine
1.4.3 Lenalidomide
1.4.4 Decitabine
1.4.5 Deferasirox
1.4.6 Others
1.5 Market by Application
1.5.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 In-Patient
1.5.3 Out-Patient
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Perspective (2015-2026)
2.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Growth Trends by Regions
2.2.1 Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Myelodysplastic Syndrome (MDS) Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Myelodysplastic Syndrome (MDS) Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Myelodysplastic Syndrome (MDS) Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Market Size
3.1.1 Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Concentration Ratio
3.2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome (MDS) Therapeutics Revenue in 2019
3.3 Myelodysplastic Syndrome (MDS) Therapeutics Key Players Head office and Area Served
3.4 Key Players Myelodysplastic Syndrome (MDS) Therapeutics Product Solution and Service
3.5 Date of Enter into Myelodysplastic Syndrome (MDS) Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020)
5.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2015-2020)
6.2 Myelodysplastic Syndrome (MDS) Therapeutics Key Players in North America (2019-2020)
6.3 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020)
6.4 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2015-2020)
7.2 Myelodysplastic Syndrome (MDS) Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020)
7.4 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2015-2020)
8.2 Myelodysplastic Syndrome (MDS) Therapeutics Key Players in China (2019-2020)
8.3 China Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020)
8.4 China Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2015-2020)
9.2 Myelodysplastic Syndrome (MDS) Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020)
9.4 Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2015-2020)
10.2 Myelodysplastic Syndrome (MDS) Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2015-2020)
11.2 Myelodysplastic Syndrome (MDS) Therapeutics Key Players in India (2019-2020)
11.3 India Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020)
11.4 India Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2015-2020)
12.2 Myelodysplastic Syndrome (MDS) Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Novartis AG
13.1.1 Novartis AG Company Details
13.1.2 Novartis AG Business Overview
13.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Introduction
13.1.4 Novartis AG Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020))
13.1.5 Novartis AG Recent Development
13.2 Celgene Corporation
13.2.1 Celgene Corporation Company Details
13.2.2 Celgene Corporation Business Overview
13.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Introduction
13.2.4 Celgene Corporation Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020)
13.2.5 Celgene Corporation Recent Development
13.3 Otsuka Pharmaceutical Co., Ltd.
13.3.1 Otsuka Pharmaceutical Co., Ltd. Company Details
13.3.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
13.3.3 Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
13.3.4 Otsuka Pharmaceutical Co., Ltd. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020)
13.3.5 Otsuka Pharmaceutical Co., Ltd. Recent Development
13.4 Sandoz Inc.
13.4.1 Sandoz Inc. Company Details
13.4.2 Sandoz Inc. Business Overview
13.4.3 Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
13.4.4 Sandoz Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020)
13.4.5 Sandoz Inc. Recent Development
13.5 Dr Reddys Laboratories Limited
13.5.1 Dr Reddys Laboratories Limited Company Details
13.5.2 Dr Reddys Laboratories Limited Business Overview
13.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Introduction
13.5.4 Dr Reddys Laboratories Limited Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020)
13.5.5 Dr Reddys Laboratories Limited Recent Development
13.6 Pharmascience Inc.
13.6.1 Pharmascience Inc. Company Details
13.6.2 Pharmascience Inc. Business Overview
13.6.3 Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
13.6.4 Pharmascience Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020)
13.6.5 Pharmascience Inc. Recent Development
13.7 Accord Healthcare Ltd
13.7.1 Accord Healthcare Ltd Company Details
13.7.2 Accord Healthcare Ltd Business Overview
13.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Introduction
13.7.4 Accord Healthcare Ltd Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020)
13.7.5 Accord Healthcare Ltd Recent Development
13.8 Mylan N.V.
13.8.1 Mylan N.V. Company Details
13.8.2 Mylan N.V. Business Overview
13.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
13.8.4 Mylan N.V. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020)
13.8.5 Mylan N.V. Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Myelodysplastic Syndrome (MDS) Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Myelodysplastic Syndrome (MDS) Therapeutics Revenue
Table 3. Ranking of Global Top Myelodysplastic Syndrome (MDS) Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Azacitidine
Table 6. Key Players of Lenalidomide
Table 7. Key Players of Decitabine
Table 8. Key Players of Deferasirox
Table 9. Key Players of Others
Table 10. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Regions (2015-2020)
Table 14. Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Myelodysplastic Syndrome (MDS) Therapeutics Market Growth Strategy
Table 20. Main Points Interviewed from Key Myelodysplastic Syndrome (MDS) Therapeutics Players
Table 21. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 22. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Players (2015-2020)
Table 23. Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelodysplastic Syndrome (MDS) Therapeutics as of 2019)
Table 24. Global Myelodysplastic Syndrome (MDS) Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Myelodysplastic Syndrome (MDS) Therapeutics Product Solution and Service
Table 27. Date of Enter into Myelodysplastic Syndrome (MDS) Therapeutics Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 30. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Share by Type (2015-2020)
Table 31. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Type (2021-2026)
Table 32. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Share by Application (2015-2020)
Table 33. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 34. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Share by Application (2021-2026)
Table 35. North America Key Players Myelodysplastic Syndrome (MDS) Therapeutics Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Myelodysplastic Syndrome (MDS) Therapeutics Market Share (2019-2020)
Table 37. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 38. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2015-2020)
Table 39. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 40. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Key Players Myelodysplastic Syndrome (MDS) Therapeutics Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Myelodysplastic Syndrome (MDS) Therapeutics Market Share (2019-2020)
Table 43. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2015-2020)
Table 45. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2015-2020)
Table 47. China Key Players Myelodysplastic Syndrome (MDS) Therapeutics Revenue (2019-2020) (Million US$)
Table 48. China Key Players Myelodysplastic Syndrome (MDS) Therapeutics Market Share (2019-2020)
Table 49. China Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 50. China Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2015-2020)
Table 51. China Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 52. China Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Key Players Myelodysplastic Syndrome (MDS) Therapeutics Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Myelodysplastic Syndrome (MDS) Therapeutics Market Share (2019-2020)
Table 55. Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2015-2020)
Table 57. Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Myelodysplastic Syndrome (MDS) Therapeutics Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Myelodysplastic Syndrome (MDS) Therapeutics Market Share (2019-2020)
Table 61. Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2015-2020)
Table 63. Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2015-2020)
Table 65. India Key Players Myelodysplastic Syndrome (MDS) Therapeutics Revenue (2019-2020) (Million US$)
Table 66. India Key Players Myelodysplastic Syndrome (MDS) Therapeutics Market Share (2019-2020)
Table 67. India Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 68. India Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2015-2020)
Table 69. India Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 70. India Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Myelodysplastic Syndrome (MDS) Therapeutics Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Myelodysplastic Syndrome (MDS) Therapeutics Market Share (2019-2020)
Table 73. Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2015-2020)
Table 75. Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2015-2020)
Table 77. Novartis AG Company Details
Table 78. Novartis AG Business Overview
Table 79. Novartis AG Product
Table 80. Novartis AG Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020) (Million US$)
Table 81. Novartis AG Recent Development
Table 82. Celgene Corporation Company Details
Table 83. Celgene Corporation Business Overview
Table 84. Celgene Corporation Product
Table 85. Celgene Corporation Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020) (Million US$)
Table 86. Celgene Corporation Recent Development
Table 87. Otsuka Pharmaceutical Co., Ltd. Company Details
Table 88. Otsuka Pharmaceutical Co., Ltd. Business Overview
Table 89. Otsuka Pharmaceutical Co., Ltd. Product
Table 90. Otsuka Pharmaceutical Co., Ltd. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020) (Million US$)
Table 91. Otsuka Pharmaceutical Co., Ltd. Recent Development
Table 92. Sandoz Inc. Company Details
Table 93. Sandoz Inc. Business Overview
Table 94. Sandoz Inc. Product
Table 95. Sandoz Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020) (Million US$)
Table 96. Sandoz Inc. Recent Development
Table 97. Dr Reddys Laboratories Limited Company Details
Table 98. Dr Reddys Laboratories Limited Business Overview
Table 99. Dr Reddys Laboratories Limited Product
Table 100. Dr Reddys Laboratories Limited Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020) (Million US$)
Table 101. Dr Reddys Laboratories Limited Recent Development
Table 102. Pharmascience Inc. Company Details
Table 103. Pharmascience Inc. Business Overview
Table 104. Pharmascience Inc. Product
Table 105. Pharmascience Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020) (Million US$)
Table 106. Pharmascience Inc. Recent Development
Table 107. Accord Healthcare Ltd Company Details
Table 108. Accord Healthcare Ltd Business Overview
Table 109. Accord Healthcare Ltd Product
Table 110. Accord Healthcare Ltd Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020) (Million US$)
Table 111. Accord Healthcare Ltd Recent Development
Table 112. Mylan N.V. Business Overview
Table 113. Mylan N.V. Product
Table 114. Mylan N.V. Company Details
Table 115. Mylan N.V. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2015-2020) (Million US$)
Table 116. Mylan N.V. Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Azacitidine Features
Figure 3. Lenalidomide Features
Figure 4. Decitabine Features
Figure 5. Deferasirox Features
Figure 6. Others Features
Figure 7. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. In-Patient Case Studies
Figure 9. Out-Patient Case Studies
Figure 10. Myelodysplastic Syndrome (MDS) Therapeutics Report Years Considered
Figure 11. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Regions: 2020 VS 2026
Figure 13. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Players in 2019
Figure 16. Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelodysplastic Syndrome (MDS) Therapeutics as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome (MDS) Therapeutics Revenue in 2019
Figure 18. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed

---